Related Experiment Video

Updated: Oct 7, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

ZC3H13 Inhibits the Progression of Hepatocellular Carcinoma through m6A-PKM2-Mediated Glycolysis and Enhances

Qibo Wang1, Haichuan Xie2, Hao Peng1

  • 1Department of Hepatobiliary Surgery, Pingxiang People's Hospital of Southern Medical University, Pingxiang, Jiangxi 337055, China.

Journal of Oncology
|January 10, 2022
PubMed
Abstract

Insights

ZC3H13, an m6A regulator, suppresses hepatocellular carcinoma (HCC) progression by inhibiting PKM2-dependent glycolysis. Its downregulation correlates with poor survival, offering therapeutic potential for HCC.

Area of Science:

  • Epigenetics
  • Molecular Oncology
  • RNA Biology

Background:

  • N6-Methyladenosine (m6A) is a key RNA epigenetic modification impacting cellular processes.
  • ZC3H13, an m6A regulator, shows prognostic significance in hepatocellular carcinoma (HCC).

Purpose of the Study:

  • To elucidate the biological functions and underlying mechanisms of ZC3H13 in HCC progression.
  • To investigate the prognostic value of ZC3H13 in HCC patients.

Main Methods:

  • Examined ZC3H13 expression in HCC and normal tissues.
  • Performed gain/loss of function assays to define ZC3H13 roles.
  • Validated ZC3H13-PKM2 interactions using molecular assays (mRNA stability, RIP, luciferase, MeRIP-qPCR).

Main Results:

  • ZC3H13 was downregulated in HCC, correlating with poor survival.
  • ZC3H13 overexpression suppressed HCC cell proliferation, migration, invasion, and enhanced apoptosis.
  • ZC3H13 modulated m6A patterns, reduced PKM2 mRNA stability, and inhibited glycolysis, sensitizing cells to cisplatin.

Conclusions:

  • ZC3H13 suppresses HCC progression via m6A-PKM2-mediated glycolysis.
  • ZC3H13 sensitizes HCC cells to cisplatin, presenting a novel therapeutic strategy.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K